Avenge Bio is a biotech startup that focuses on developing innovative therapeutics to combat solid tumors. The company's primary product is its proprietary LOCOcyteTM platform, which is designed to deliver cytokines and other immunomodulatory molecules in a controlled manner. This approach aims to stimulate strong local and systemic anti-tumor immune responses, without the side effects associated with traditional immunotherapies.

The company's target market includes patients suffering from hard-to-treat solid tumors. Avenge Bio's business model revolves around the research, development, and commercialization of its LOCOcyteTM platform. The company generates revenue through the sales of its therapeutics and through partnerships with other healthcare entities.

One of the company's ongoing projects is a Phase 1/2 study of AVB-001, a treatment for patients with serous adenocarcinoma of the ovary. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2), a type of protein that regulates the activities of white blood cells that are responsible for immunity. The product is delivered directly into the peritoneal cavity, the space within the abdomen that contains the intestines, stomach, and liver.

Avenge Bio was founded by a team of experienced biotech executives, including CEO Michael Heffernan, a seasoned biopharmaceutical entrepreneur with over three decades of experience. The company's work is backed by leading healthcare investors such as Longitude Capital, CAM Capital, Perceptive Xontogeny, and Rock Springs.

Keywords: Biotech, Solid Tumors, Therapeutics, LOCOcyteTM Platform, Cytokines, Immunomodulatory Molecules, Serous Adenocarcinoma, AVB-001, Interleukin-2, Healthcare Investors.